Prof. Aron Popovtzer

Director of the Sharett Oncology Institute, Hadassah Medical Center
  • Prof. Aron Popovtzer is the Director of the Sharett Oncology Institute, Hadassah Medical Center
  • He graduated the Hadassah–Hebrew University School of Medicine.
  • Interned at Beilinson Hospital (Rabin medical center), where he completed his residency in the Ear, Nose and Throat Department
  • Prof. Aron Popovtzer completed another double residency in oncology and radiotherapy, and since 2009 is an expert in both fields.
  • Specialized in head and neck cancer at the University of Michigan in Ann Arbor.
  • He also completed training in brachytherapy at “Beth Israel” Hospital in New York and additional training at “Memorial” Hospital in New York in the field of radiosurgery, with an emphasis on targeted radiation to the spine, and thyroid cancer.
  • Prof. Aron Popovtzer specializes in personalized treatments and immunotherapy and biological treatments for these diseases and in all fields of radio-surgery; Treatment of acoustic neurinoma, recurrent head and neck cancer and all tumors with spinal metastases.
  • Prof. Aron Popovtzer also serves as the chairman of the Israeli Society for Head and Neck Tumors, and Israel’s representative in the World Society for Head and Neck Cancer. Active in the European Society (EORTC), and senior lecturer at Tel Aviv University.
  • Prof. Popovtzer has received several awards for the contributions to the scientific community.
Recent Key Publications
  • Macrophages Upregulate Estrogen Receptor Expression in the Model of Obesity-Associated Breast Carcinoma. Cells,2022. Daniela Nahmias Blank, Esther Hermano, Amir Sonnenblick, Ofra Maimon, Ariel M. Rubinstein, Emmy Drai, Bella Maly, Israel Vlodavsky, Aron Popovtzer, Tamar Peretz, Amichay Meirovitz and Michael Elkin
  • Antibody Delivery into the Brain by Radiosensitizer Nanoparticles for Targeted Glioblastoma Therapy. Journal of Nanotheranostics, 2022. Omer Gal, Oshra Betzer, Liat Rousso-Noori, Tamar Sadan, Menachem Motiei, Maxim Nikitin, Dinorah Friedmann-Morvinski, Rachela Popovtzer and Aron Popovtzer
  • Patterns of metastases progression- The linear parallel ratio. PLoS One, 2022. Ofer N Gofrit, Ben Gofrit , Yuval Roditi , Aron Popovtzer , Steve Frank , Jacob Sosna, S Nahum Goldberg.
  • Effect of irradiation on cytokine production in cancer patients. The International Journal of Biological Markers, 2022. Meirovitz A, Gross M, Cohen S, Popovtzer A, Barak V.
  • Oncology Treatments during the COVID-19 Pandemic in Israel: the ONCOR Study. Israel Medical Association Journal, 2021. Galit Hirsh-Yechezkel, Angela Chetrit, Sivan Ben Avraham, Abed Agbarya, Alexander Yakobson, Noam Asna, Gil Bar-Sela, Irit Ben-Aharon, Noa Efrat Ben-Baruch, Raanan Berger, Ronen Brenner, Maya Gottfried, Shani Paluch-Shimon, Raphael Pfeffer, Aron Popovtzer, Larisa Ryvo, Valeriya Semenisty, Ayelet Shai, Katerina Shulman, Jamal Zidan, Ido Wolf.
  • Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma. Oncology, 2021. Nir Hirshoren , Issa Al-Kharouf , Jeffrey M Weinberger, Ron Eliashar, Aron Popovtzer , Ariela Knaanie , Yakov Fellig, Tzahi Neuman, Karen Meir, Alexander Maly , Gilad W Vainer.
  • ‘Golden’ exosomes as delivery vehicles to target tumors and overcome intratumoral barriers: in vivo tracking in a model for head and neck cancer. Biomaterials Science, 2021. Oded Cohen, Oshra Betzer, Noy Elmaliach-Pnini, Menachem Motiei, Tamar Sadan, Moran Cohen-Berkman, Or Dagan, Aron Popovtzer, Ady Yosepovich, Hana Barhom, Shulamit Michaelif and Rachela Popovtzer.
  • COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma. European Journal of Nuclear Medicine & Molecular Imaging, 2021.  Avner M, Orevi M, Caplan N, Popovtzer A, Lotem MC, Cohen JE.

Cancer Treatment in Israel - oncology

The Sharett Institute of Oncology - Cancer Treatment at Hadassah Hospital, Israel

The Sharett Institute of Oncology was established at the Hebrew University – Hadassah Medical Center in 1977 as a national institute for the prevention, treatment, and research of cancer in Israel. The Sharett Institute of Oncology, which serves the population of Jerusalem and surrounding area, is a referral center for cancer patients from all over the world. More than 3,500 new patients are referred to the Sharett Institute each year.

The Sharett Institute strives for excellence, reliability, and compassion while treating cancer patients. The Sharett Institute strives to provide the best and most innovative methods available while addressing the special emotional needs of each and every patient. Alongside the administration of standard cancer treatment, our physicians include our patients in international clinical trials and develop experimental and cutting-edge cancer treatment approaches in our Oncology Department. To achieve these goals, the Sharett Institute operates special units that are inextricably linked. These units include infrastructure units, specialized units, and interdisciplinary units.
The clinical units work closely with the our advanced research laboratories. Researchers, doctors and lab technicians work together as a team to research new treatments and spheres relating to cancer, enabling rapid and maximum use of research outcomes in cancer treatment Israel, diagnosis and prevention.

Infrastructure Units


Specialized and Interdisciplinary Units

Skip to content